These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 17183065

  • 21. Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma.
    Zhang W, Li C, Wang J, He C.
    Hepatogastroenterology; 2012; 59(113):141-6. PubMed ID: 21940365
    [Abstract] [Full Text] [Related]

  • 22. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
    Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F.
    Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
    [Abstract] [Full Text] [Related]

  • 23. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
    Ragnarsson GB, Mikaelsdottir EK, Vidarsson H, Jónasson JG, Olafsdóttir K, Kristjánsdóttir K, Kjartansson J, Ogmundsdóttir HM, Rafnar T.
    Br J Cancer; 2000 Dec; 83(12):1715-21. PubMed ID: 11104571
    [Abstract] [Full Text] [Related]

  • 24. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck.
    Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, Spitz MR, Wei Q.
    Clin Cancer Res; 2006 Sep 15; 12(18):5596-602. PubMed ID: 17000697
    [Abstract] [Full Text] [Related]

  • 25. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.
    Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T.
    Clin Cancer Res; 2000 Sep 15; 6(9):3560-4. PubMed ID: 10999744
    [Abstract] [Full Text] [Related]

  • 26. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis.
    Zhang H, Sun XF, Synnerstad I, Rosdahl I.
    Cancer J; 2007 Sep 15; 13(4):233-7. PubMed ID: 17762757
    [Abstract] [Full Text] [Related]

  • 27. Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer.
    Lu P, Zhu XQ, Xu ZL, Zhou Q, Zhang J, Wu F.
    Surgery; 2009 Mar 15; 145(3):286-93. PubMed ID: 19231581
    [Abstract] [Full Text] [Related]

  • 28. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
    Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K.
    Int J Oncol; 2001 Jan 15; 18(1):33-9. PubMed ID: 11115536
    [Abstract] [Full Text] [Related]

  • 29. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection.
    Jung YJ, Kim YJ, Kim LH, Lee SO, Park BL, Shin HD, Lee HS.
    Intervirology; 2007 Jan 15; 50(5):369-76. PubMed ID: 17938571
    [Abstract] [Full Text] [Related]

  • 30. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
    Shukuwa T, Katayama I, Koji T.
    Mod Pathol; 2002 Apr 15; 15(4):387-96. PubMed ID: 11950912
    [Abstract] [Full Text] [Related]

  • 31. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer.
    Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B.
    Cancer Detect Prev; 2007 Apr 15; 31(3):225-32. PubMed ID: 17561354
    [Abstract] [Full Text] [Related]

  • 32. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.
    Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D.
    J Natl Cancer Inst; 2004 Jul 07; 96(13):1030-6. PubMed ID: 15240787
    [Abstract] [Full Text] [Related]

  • 33. Elevated Fas expression is related to increased apoptosis of circulating CD8+ T cell in patients with gastric cancer.
    Yoshikawa T, Saito H, Osaki T, Matsumoto S, Tsujitani S, Ikeguchi M.
    J Surg Res; 2008 Aug 07; 148(2):143-51. PubMed ID: 18561948
    [Abstract] [Full Text] [Related]

  • 34. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
    Yoshimura C, Nomura S, Kanazawa S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S.
    J Cancer Res Clin Oncol; 2002 Nov 07; 128(11):581-8. PubMed ID: 12458337
    [Abstract] [Full Text] [Related]

  • 35. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE, Shanahan F, O'Connell J, Houston AM.
    Cancer Res; 2005 Nov 01; 65(21):9817-23. PubMed ID: 16267003
    [Abstract] [Full Text] [Related]

  • 36. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population.
    Verim L, Timirci-Kahraman O, Akbulut H, Akbas A, Ozturk T, Turan S, Yaylim I, Ergen A, Ozturk O, Isbir T.
    In Vivo; 2014 Nov 01; 28(3):397-402. PubMed ID: 24815844
    [Abstract] [Full Text] [Related]

  • 37. Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients.
    Marín LA, Muro M, Moya-Quiles MR, Miras M, Minguela A, Bermejo J, Sanchez-Bueno F, Parrilla P, Alvarez-López MR.
    Tissue Antigens; 2006 Feb 01; 67(2):117-26. PubMed ID: 16441482
    [Abstract] [Full Text] [Related]

  • 38. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U, Gierschner D, Welchner T, Wetterauer U.
    Anticancer Res; 2003 Feb 01; 23(1A):433-7. PubMed ID: 12680244
    [Abstract] [Full Text] [Related]

  • 39. Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast.
    Yakirevich E, Maroun L, Cohen O, Izhak OB, Rennert G, Resnick MB.
    J Pathol; 2000 Oct 01; 192(2):166-73. PubMed ID: 11004692
    [Abstract] [Full Text] [Related]

  • 40. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Kim R, Emi M, Tanabe K, Uchida Y, Toge T.
    Cancer; 2004 Jun 01; 100(11):2281-91. PubMed ID: 15160330
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.